Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 376, Issue 9, Pages 848-855Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1609677
Keywords
-
Categories
Funding
- Assistance Publique-Hopitaux de Paris
- INSERM
Ask authors/readers for more resources
Sickle cell disease results from a homozygous missense mutation in the beta-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector-mediated addition of an antisickling beta-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling beta-globin remained high (approximately 50% of beta-like-globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available